Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Not Confirmed
Not Confirmed
22-24 April, 2025
Not Confirmed
Not Confirmed
22-25 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Industry Trade Show
Not Confirmed
22-24 April, 2025
Industry Trade Show
Not Confirmed
22-25 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
25 Sep 2024
// ACCESSWIRE
https://www.accesswire.com/923249/prevail-partners-and-prevail-infoworks-enter-into-strategic-investment-and-clinical-alliance-with-kairos-pharma-ltd
17 Apr 2024
// James Waldron FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/lillys-prevail-walks-away-gene-editing-collab-precision
18 Jul 2023
// PRESS RELEASE
https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-announces-research-evaluation-and-option
07 Jul 2023
// Gabrielle Masson FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/lillys-prevail-revises-26b-biobucks-deal-precision-taking-more-preclinical-responsibilities
17 May 2023
// Gabrielle Masson FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/lillys-prevail-inks-15b-pact-doudnas-scribe-crispr-tech
05 Jan 2023
// Delilah Alvarado BIOPHARMADIVE
https://www.biopharmadive.com/news/capsida-prevail-lilly-aav-gene-therapy-partner/639591/
Details:
Acquisition will set up a gene therapy program at Lilly, based on Prevail's portfolio of neuroscience assets, including the lead candidate, PR001, and will broaden Lilly's commitment to use novel modalities to address fatal genetic forms of neurodegenerative disease.
Lead Product(s): PR001,Methylprednisolone,Sirolimus
Therapeutic Area: Neurology Brand Name: PR001
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Eli Lilly
Deal Size: $1,040.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 22, 2021
Lead Product(s) : PR001,Methylprednisolone,Sirolimus
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : $1,040.0 million
Deal Type : Acquisition
Lilly Completes Acquisition of Prevail Therapeutics
Details : Acquisition will set up a gene therapy program at Lilly, based on Prevail's portfolio of neuroscience assets, including the lead candidate, PR001, and will broaden Lilly's commitment to use novel modalities to address fatal genetic forms of neurodegenera...
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 22, 2021
Details:
Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease.
Lead Product(s): PR001,Methylprednisolone,Sirolimus
Therapeutic Area: Genetic Disease Brand Name: PR001
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Eli Lilly
Deal Size: $1,040.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 15, 2020
Lead Product(s) : PR001,Methylprednisolone,Sirolimus
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : $1,040.0 million
Deal Type : Acquisition
Lilly Announces Agreement to Acquire Prevail Therapeutics
Details : Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disea...
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 15, 2020
Details:
The Company also announced that the FDA has granted Rare Pediatric Disease Designation for PR001 for the treatment of neuronopathic Gaucher disease (nGD), the most severe form of the condition.
Lead Product(s): PR001
Therapeutic Area: Genetic Disease Brand Name: PR001
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 02, 2020
Lead Product(s) : PR001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prevail Therapeutics’ PR001 Gets Orphan Drug Designation By FDA
Details : The Company also announced that the FDA has granted Rare Pediatric Disease Designation for PR001 for the treatment of neuronopathic Gaucher disease (nGD), the most severe form of the condition.
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 02, 2020
Details:
PR006 is an investigational AAV9 gene therapy delivering the GRN gene and is being developed as a potential therapy for patients with frontotemporal dementia with GRN mutations.
Lead Product(s): PR006,Methylprednisolone,Sirolimus
Therapeutic Area: Neurology Brand Name: PR006
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 30, 2020
Lead Product(s) : PR006,Methylprednisolone,Sirolimus
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PR006 is an investigational AAV9 gene therapy delivering the GRN gene and is being developed as a potential therapy for patients with frontotemporal dementia with GRN mutations.
Product Name : PR006
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 30, 2020
Details:
The Company expects to initiate enrollment of the Phase 1/2 PROVIDE clinical trial of PR001 for Type 2 Gaucher disease patients in the fourth quarter of 2020 and currently anticipates it will provide the next update on PR001 biomarker and safety data for nGD in 2021.
Lead Product(s): PR001,Methylprednisolone,Sirolimus
Therapeutic Area: Neurology Brand Name: PR001
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 18, 2020
Lead Product(s) : PR001,Methylprednisolone,Sirolimus
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Company expects to initiate enrollment of the Phase 1/2 PROVIDE clinical trial of PR001 for Type 2 Gaucher disease patients in the fourth quarter of 2020 and currently anticipates it will provide the next update on PR001 biomarker and safety data for...
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 18, 2020
Details:
The Company is developing PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). Prevail expects to start enrollment of the PROVIDE Phase 1/2 clinical trial of PR001 in the second half of 2020.
Lead Product(s): PR001,Methylprednisolone,Sirolimus
Therapeutic Area: Genetic Disease Brand Name: PR001
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 27, 2020
Lead Product(s) : PR001,Methylprednisolone,Sirolimus
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Company is developing PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). Prevail expects to start enrollment of the PROVIDE Phase 1/2 clinical trial of PR001 in the second half of 2020.
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 27, 2020
Details:
Company Advancing its Phase 1/2 Clinical Trial for the Treatment of Neuronopathic Gaucher Disease and Expects to Initiate Patient Dosing in First Half of 2020.
Lead Product(s): PR001
Therapeutic Area: Oncology Brand Name: PR001
Study Phase: IND EnablingProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 01, 2020
Lead Product(s) : PR001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prevail Therapeutics Provides PR001 Program Update
Details : Company Advancing its Phase 1/2 Clinical Trial for the Treatment of Neuronopathic Gaucher Disease and Expects to Initiate Patient Dosing in First Half of 2020.
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 01, 2020
Details:
PR006 is being developed as a potential one-time gene therapy for FTD-GRN, a progressive neurodegenerative disease caused by mutations in the GRN gene that reduce production of progranulin.
Lead Product(s): PR006
Therapeutic Area: Neurology Brand Name: PR006
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 27, 2020
Lead Product(s) : PR006
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PR006 is being developed as a potential one-time gene therapy for FTD-GRN, a progressive neurodegenerative disease caused by mutations in the GRN gene that reduce production of progranulin.
Product Name : PR006
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 27, 2020
Details:
Preclinical data demonstrate potential of Prevail’s AAV gene therapy approach to slow or halt progression in multiple neurodegenerative diseases.
Lead Product(s): PR001
Therapeutic Area: Genetic Disease Brand Name: PR001
Study Phase: PreclinicalProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 29, 2020
Lead Product(s) : PR001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical data demonstrate potential of Prevail’s AAV gene therapy approach to slow or halt progression in multiple neurodegenerative diseases.
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 29, 2020
Details:
The presentation will highlight preclinical data related to PR001 for PD-GBA and the design of PROPEL, Phase 1/2 clinical trial to evaluate the safety and efficacy of PR001 in patients with PD-GBA.
Lead Product(s): PR001
Therapeutic Area: Neurology Brand Name: PR001
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 31, 2020
Lead Product(s) : PR001
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prevail Therapeutics to Present at AAT-AD/PD Focus Meeting 2020: Advances in Alzheimer’s and Par...
Details : The presentation will highlight preclinical data related to PR001 for PD-GBA and the design of PROPEL, Phase 1/2 clinical trial to evaluate the safety and efficacy of PR001 in patients with PD-GBA.
Product Name : PR001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 31, 2020
ABOUT THIS PAGE